Bioequivalence study of phenazopyridine hydrochloride 100 mg tablet
Not Applicable
Recruiting
- Conditions
- ---.
- Registration Number
- IRCT20230222057495N11
- Lead Sponsor
- Mehr Darou Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Healthy volunteer between 18 and 55 years old.
Body mass index less than 30 kg per square meter.
All candidates must be non-smokers.
Exclusion Criteria
Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg
Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The maximum plasma concentration of phenazopyridine hydrochloride. Timepoint: Before taking the drug and: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours after taking the drug. Method of measurement: Liquid chromatography-mass spectrometry.
- Secondary Outcome Measures
Name Time Method